1 week Ago By ABMN Staff
Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Get Free Report ) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $19.
75 and last traded at $21.91, with a volume of 832315 shares changing hands. The stock had previously closed at $22.
07. Analyst Upgrades and Downgrades A number of analysts have commented on the company. HC Wainwright lifted their price target on Kymera Therapeutics from $54.
00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $60.
00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th.
BTIG Research initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company.
Finally, Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company.
Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.
36. Get Our Latest Research Report on Kymera Therapeutics Kymera Therapeutics Trading Down 0.3 % Kymera Therapeutics ( NASDAQ:KYMR – Get Free Report ) last posted its quarterly earnings results on Thursday, February 27th.
The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.
12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.
26%. The business had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.
81 million. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.
79 EPS for the current year. Insider Transactions at Kymera Therapeutics In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.
45, for a total value of $68,238.45. Following the transaction, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.
25. The trade was a 2.72 % decrease in their position.
The transaction was disclosed in a document filed with the SEC, which is available through the SEC website . Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction that occurred on Monday, March 3rd.
The shares were sold at an average price of $30.45, for a total transaction of $42,112.35.
Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold a total of 10,659 shares of company stock worth $324,567 in the last ninety days. Insiders own 15.
82% of the company’s stock. Institutional Inflows and Outflows A number of large investors have recently added to or reduced their stakes in KYMR. Wellington Management Group LLP lifted its stake in shares of Kymera Therapeutics by 14.
9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after purchasing an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 14.
4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after buying an additional 650,000 shares during the last quarter. Deerfield Management Company L.
P. Series C purchased a new position in Kymera Therapeutics during the fourth quarter worth about $23,856,000. Boxer Capital Management LLC acquired a new stake in shares of Kymera Therapeutics during the fourth quarter valued at about $17,098,000.
Finally, Janus Henderson Group PLC raised its stake in shares of Kymera Therapeutics by 2,397.9% in the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after acquiring an additional 362,276 shares during the period.
About Kymera Therapeutics ( Get Free Report ) Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. Featured Stories Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
